



Volker Moebus

Contact

Volker Moebus

Publications (5)

Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Gomez H, Gombos A, Coccia-Portugal M, Tseng L, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. *Eur J Cancer* 2022; 181:92-101.

Thill M, Mundhenke C, Moebus V, Maass N, Lux M, Luftner D, Loibl S, Kümmel S, Kühn T, Kreipe H, Park-Simon T, Reimer T, Rhiem K, Wöckel A, Witzel I, Thomssen C, Stickeler E, Solomayer E, Solbach C, Schneeweiss A, Schmidt M, Rody A, Huober J, Heil J, Banys-Paluchowski M, Albert U, Müller V, Janni W, Friedrich M, Krug D, Jackisch C, Kolberg-Liedtke C, Untch M, Bauerfeind I, Blohmer J, Budach W, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Diel I, Dall P, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. *Breast Care (Basel)* 2020; 15:294-309.

Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Response. *J Natl Cancer Inst* 2014; 106:djt452.

Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. *J Natl Cancer Inst* 2013; 105:1018-26.

Moebus V, Konecny G, Kreienberg R, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Jackisch C, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. *J Clin Oncol* 2010; 28:2874-80.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch